Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. (MRTX): 14 pipeline candidates · ~20 mo cash runway · 13 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
20.0 months
D/E 0.19 · 0% dilution
Lead: Approved
14 candidates
N/A
N/A
A transparent, data-derived signal for Mirati Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$259.3M
Quarterly Burn
$143.7M
Runway
20.0 mo
Revenue
$16.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (14 candidates)
| Drug | Phase |
|---|---|
| adagrasib oral dose of | Phase 2 |
| afatinib | Phase 1/Phase 2 |
| cetuximab | Phase 1/Phase 2 |
| enfortumab vedotin-ejfv | Phase 2/Phase 3 |
| folfiri regimen | Phase 3 |
| krazati | Approved |
| leucovorin | Phase 2 |
| mfolfox6 regimen | Phase 3 |
| mrtx0902 | Phase 1 |
| mrtx1133 | Preclinical |
Showing 10 of 14 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Mirati Therapeutics, Inc.'s pipeline?
Mirati Therapeutics, Inc. (MRTX) has 14 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Mirati Therapeutics, Inc.'s lead drug candidate?
Mirati Therapeutics, Inc.'s most advanced tracked candidate is adagrasib oral dose of (Phase 2) for Advanced NSCLC.
What is Mirati Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Mirati Therapeutics, Inc. has approximately 20.0 months of cash runway.
Who is the CEO of Mirati Therapeutics, Inc.?
David Meek is the chief executive officer of Mirati Therapeutics, Inc. (MRTX).
Get the full picture on Mirati Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.